U.S. Entertainment Stock News

NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Exploring US High Growth Tech Stocks In December 2025

As the U.S. stock market continues to reach new heights with the S&P 500 and Dow Jones Industrial Average setting all-time records, investor attention remains sharply focused on high growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that not only demonstrate strong innovation and adaptability but also show resilience amidst broader market trends and economic indicators.
NYSE:NET
NYSE:NETIT

High Growth Companies With Strong Insider Confidence December 2025

As the U.S. stock market celebrates record highs with the S&P 500 and Dow Jones Industrial Average setting new closing records, investors are increasingly focusing on companies that demonstrate both growth potential and strong insider confidence. In this buoyant market environment, stocks with high insider ownership can be particularly appealing as they often signal management's belief in the company's future prospects, aligning their interests closely with those of shareholders.
NYSE:PLOW
NYSE:PLOWMachinery

Top Dividend Stocks To Consider In December 2025

As the U.S. stock market continues to reach new heights with the Dow Jones and S&P 500 setting fresh records, investors are increasingly seeking stable returns amidst a backdrop of rising gold and silver prices. In this dynamic environment, dividend stocks offer a compelling option for those looking to benefit from consistent income while participating in potential market gains.
NasdaqGM:RAPT
NasdaqGM:RAPTBiotechs

RAPT Therapeutics (RAPT) Is Up 8.0% After Index Additions And Trial Progress News Has The Bull Case Changed?

In December 2025, RAPT Therapeutics, Inc. was added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, following recent clinical and financing milestones. This index inclusion underscores how ozureprubart’s progress, combined with a US$250,000,000 equity raise extending cash runway into mid-2028, is sharpening investor focus on RAPT’s pipeline. We’ll now examine how ozureprubart’s Phase 2b food allergy trial clearance shapes RAPT Therapeutics’...
NYSE:GHG
NYSE:GHGHospitality

GreenTree Hospitality (NYSE:GHG) Q3 Revenue Drop Tests Bullish China Recovery Narrative

GreenTree Hospitality Group (NYSE:GHG) has posted its Q3 2025 numbers, reporting revenue of CNY 303.6 million, basic EPS of CNY 0.60 and net income of CNY 60.8 million, with a trailing twelve month net profit margin of 15.2% compared with 14% a year earlier. The company has seen quarterly revenue move from CNY 356.98 million in Q3 2024 to CNY 303.61 million in Q3 2025, while basic EPS shifted from CNY 0.65 to CNY 0.60 over the same period. This sets up a results season where steady margins...